Progenics Pharmaceuticals, Inc. (PGNX) Announces Fourth Quarter And Year-End 2013 Financial Results And Initiates Clinical Development Of Small Molecule Targeted Therapeutic
3/13/2014 8:54:31 AM
TARRYTOWN, N.Y., March 13, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the fourth quarter and year-end 2013. The company also announced that it is initiating clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for the treatment of prostate cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by